Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1

被引：4

作者：

Rossi, John M. ^{[1
]}

Galon, Jerome ^{[2
]}

Turcan, Sarah ^{[3
]}

Danan, Corinne ^{[3
]}

Locke, Frederick L. ^{[4
]}

Neelapu, Sattva S. ^{[5
]}

Miklos, David B. ^{[6
]}

Jacobson, Caron A. ^{[7
]}

Lekakis, Lazaros J. ^{[8
]}

Lin, Yi ^{[9
]}

Ghobadi, Armin ^{[10
]}

Go, William Y. ^{[1
]}

Bot, Adrian ^{[1
]}

机构：

[1] Kite, Santa Monica, CA USA

[2] UPMC Univ Paris, Sorbonne Univ, Univ Paris Descartes, INSERM, Paris, France

[3] HalioDx, Marseille, France

[4] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Stanford Univ, Sch Med, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-LB-016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-016

引用

页数：2

共 50 条

[21] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Zhang, Muchen
Fang, Ying
Xu, Pengpeng
Cheng, Shu
Wang, Li
Zhao, Wei-Li
BLOOD, 2018, 132
[22] Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1
Neelapu, Sattva S.
Jacobson, Caron A.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Spooner, Clare
Kim, Jenny J.
Miao, Harry
Xue, Allen Xiaodong
Zheng, Yan
Locke, Frederick L.
BLOOD, 2023, 142
[23] Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Neelapu, Sattva S.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David B.
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianqing
Rossi, John M.
Locke, Frederick L.
BLOOD, 2020, 135 (23) : 2106 - 2109
[24] Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 16 - 18
[25] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Topp, Max
Van Meerten, Tom
Houot, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duhrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose'
BLOOD, 2019, 134
[26] Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
Logue, Jennifer Marilyn
Krivenko, Gabriel S.
Larson, Victoria
Bachmeier, Christina A.
Chavez, Julio C.
Davila, Marco L.
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien D.
Pinilla-Ibarz, Javier
Shah, Bijal D.
Dholaria, Bhagirathbhai R.
Jain, Michael D.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) plus Utomilumab Patients with Refractory Large B Cell Lymphoma
Reshef, Ran
Miklos, David B.
Timmerman, John M.
Jacobson, Caron A.
Bennani, Nabila N.
Rossi, John M.
Sherman, Marika
Zheng, Lianqing
Sun, Jennifer
Palluconi, Gabrielle
Kim, Jenny J.
Jain, Michael D.
BLOOD, 2019, 134
[28] CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)
Locke, F. L.
Neelapu, S. S.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Lin, Y.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J.
Navale, L.
Jiang, Y.
Aycock, J.
Elias, M.
Wiezorek, J.
Go, W. Y.
HAEMATOLOGICA, 2017, 102 : 172 - 172
[29] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
[30] Preliminary results of earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma
Topp, M. S.
van Meerten, T.
Wermke, M.
Lugtenburg, P. J.
Minnema, M. C.
Song, K. W.
Thieblemont, C.
Jiang, Y.
Plaks, V
Kerber, A.
Kersten, M. J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 65 - 66

← 1 2 3 4 5 →